Open Nav

Please submit your session questions in advance at http://bit.ly/BIOCEO19question

Immunicum AB

  • Carlos de Sousa, Immunicum AB

Immunicum is establishing a unique immuno-oncology approach through the development of allogeneic, off-the-shelf cell-based therapies. The company’s lead product ilixadencel, consisting of pro-inflammatory allogeneic dendritic cells, has the potential to improve survival outcomes and quality of life by priming the patient’s own immune system to fight cancer. Ilixadencel is currently in a Phase 2 controlled study in renal cell carcinoma (kidney cancer), has completed Phase 1/2 studies in kidney cancer and liver cancer, and has initiated a Phase 1b/2 combination study with checkpoint inhibitors in Head and Neck (HNSCC), Lung (NSCLC) and gastric cancer by the end of 2018. Immunicum is a public company at the Nasdaq Stockholm and has recently raised USD 39 million.

  • Date:Monday, February 11
  • Time:3:00 PM - 3:15 PM
  • Room:Herald/Soho
  • Location:7th Floor
  • Session Type:Company Presentation
  • Please submit your session questions in advance at:http://bit.ly/BIOCEO19question
  • Company Presentation - Presentation Type:Publicly Traded Company
  • Submission ID:23247
  • Goal for Presentation:Increase awareness and attract new investors
  • Company Website:www.immunicum.com
  • Company HQ City:Stockholm
  • Company HQ Country:Sweden
  • Ticker:IMMU.ST
  • Exchange:Nasdaq Stockholm
  • CEO/Top Company Official:Carlos de Sousa
  • Year Founded:2002
  • Main Therapeutic Focus:Oncology
  • Lead Product in Development:ilixadencel
  • Development Phase of Primary Product:Phase II
Speakers
Carlos de Sousa
Immunicum AB
Back